Search results
Results from the WOW.Com Content Network
Yudin was born in Moscow into the family of a factory owner. In 1911, Yudin became a medical student at the University of Moscow. In the fall of 1914, after the beginning of the First World War, Yudin was called into the army as a junior doctor. During the war, Yudin was wounded three times. He was awarded the Cross of St. George for bravery. [1]
Russian surgeon Sergei Yudin pioneered the transfusion of cadaveric blood and performed this successfully for the first time on March 23, 1930. Yudin also reported his first seven clinical transfusions with cadaveric blood at the Fourth Congress of Ukrainian Surgeons at Kharkiv in September 1930.
Young blood transfusion refers to transfusing blood specifically from a young person into an older one with the intention of creating a health benefit. [1] The efficacy and safety of young blood transfusions for anti-aging purposes remain a subject of debate in the scientific community, with limited clinical evidence in humans.
Nikolai Yudin (1898–after 1966), Russian historian of religion; Pavel Yudin (1899–1968), Russian Soviet philosopher, diplomat, and Communist party figure; Sergei Yudin (surgeon) (1891–1954), Russian surgeon, military doctor, inventor, academician, and blood transfusion pioneer; Sergei Yudin (tenor) (1889–1963), Russian operatic tenor
Myofascial release (MFR, self-myofascial release) is an alternative medicine therapy claimed to be useful for treating skeletal muscle immobility and pain by relaxing contracted muscles, improving blood and lymphatic circulation and stimulating the stretch reflex in muscles.
Articular cartilage, most notably that which is found in the knee joint, is generally characterized by very low friction, high wear resistance, and poor regenerative qualities. It is responsible for much of the compressive resistance and load bearing qualities of the knee joint and, without it, walking is painful to impossible.
Tentative evidence of prolotherapy benefit was reported in a 2011 review. [5] [7] One 2017 review found evidence of benefit from low-quality studies. [14] A 2017 review described the evidence as moderate for knee osteoarthritis. [15] A 2016 review found benefit but there was a moderate degree of variability between trials and risk of bias. [16]
Because any medication that could reduce the inflammation of CPPD bears a risk of causing organ damage, treatment is not advised if the condition is not causing pain. [4] For acute pseudogout, treatments include intra-articular corticosteroid injection, systemic corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), or, on occasion ...